摘要
目的探究阿帕他胺治疗转移性激素敏感前列腺癌的应用。方法选取2019年6月至2022年6月在九江市第一人民医院诊断为转移性激素敏感前列腺癌(mHSPC)的患者80例,按照抽签法分为观察组和对照组,每组各40例。对照组采用比卡鲁胺联合雄激素剥夺治疗(ADT),观察组采用阿帕他胺联合ADT治疗。评估两组临床疗效、前列腺特异性抗原(PSA)应答时间、至PSA进展时间、至去势抵抗性前列腺癌(CRPC)时间以及药物相关不良反应。结果观察组患者临床总有效率高于对照组,差异有统计学意义(P<0.05);观察组患者PSA应答时间短于对照组,差异有统计学意义(P<0.05);观察组患者至PSA进展时间长于对照组,差异有统计学意义(P<0.05);观察组患者至CRPC时间长于对照组,差异有统计学意义(P<0.05);两组的药物不良反应发生率比较,差异无统计学意义(P>0.05)。结论阿帕他胺联合ADT治疗mHSPC患者效果较好,能更快速实现PSA应答,延缓PSA进展及至CRPC时间,安全性相对较高,药物相关不良反应较低。
Objective To investigate the application of Apalutamide in the treatment of metastatic hormone-sensitive prostate cancer.Methods A total of 80 patients diagnosed with metastatic hormone-sensitive prostate cancer(mHSPC)in the First People's Hospital of Jiujiang from June 2019 to June 2022 were selected and divided into observation group and control group according to lottery method,with 40 cases in each group.The control group was treated with Bicalutamide combined with androgen deprivation therapy(ADT),and the observation group was treated with Apalutamide combined with ADT.Clinical efficacy,prostate-specific antigen(PSA)response time,time to PSA progression,time to castration-resistant prostate cancer(CRPC),and drug-related adverse reactions were evaluated in both groups.Results The total clinical effective rate of observation group was higher than that of control group,the difference was statistically significant(P<0.05).The PSA response time of observation group was shorter than that of control group,and the difference was statistically significant(P<0.05).The progression time of PSA in observation group was longer than that in control group,and the difference was statistically significant(P<0.05).The time to CRPC in observation group was significantly longer than that in control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse drug reactions between the two groups(P>0.05).Conclusion The new endocrine drug Apalutamide combined with ADT is effective in the treatment of mHSPC patients,which can realize PSA response more quickly,delay PSA progression to CRPC,and have relatively high safety and low drug-related adverse reactions.
作者
蒋轶
叶韬
高加胜
刘启航
张海峰
JIANG Yi;YE Tao;GAO Jiasheng;LIU Qihang;ZHANG Haifeng(The Second Department of Oncology,the First People's Hospital of Jiujiang City,Jiangxi Province,Jiujiang332001,China;Department of Urology,the First People's Hospital of Jiujiang,Jiangxi Province,Jiujiang332001,China)
出处
《中国当代医药》
CAS
2024年第5期95-98,共4页
China Modern Medicine
基金
江西省卫生健康委科技计划项目(202311467)。
